Search

The identification of synovial crystals is important for diagnosing rheumatic diseases. Currently, rheumatologists worldwide use compensated polarized light microscopy (CPLM) for crystal identification, but this technique is flawed. Raman spectroscopy might offer an objective, accurate alternative. We have tested Raman hyperspectral imaging on synovial fluid samples of 28 patients with swollen joints, measuring 5–10 crystals in each of these. Reference spectra for identification were measured using patient material, synthetic compounds, and oxalate kidney stones. Additionally, RRUFF and PANGAEA Raman databases were used to identify spectra. We identified the classical pathological crystals monosodium urate for gout and calcium pyrophosphate for calcium pyrophosphate deposition disease (CPPD). Hydroxyapatite, lipid spherules, and calcium oxalate monohydrate have also been observed and had been previously identified in synovial fluids. Other crystals, which were not previously observed in synovial fluid using CPLM, have been identified as well: calcite, aragonite, anatase, rutile, thenardite, dolomite, and a carotenoid. In addition, we found combinations of crystals in 13 out of 28 patients. We propose that the observed large variation of detectable crystals from a small population of patients and a small number of crystals per patient has significant ramifications for the use of compensated polarized light microscopy for the diagnosis of gout and CPPD. Further studies are required to learn the clinical significance of these crystals in human arthritis. [ABSTRACT FROM AUTHOR]

EpCAM expressing circulating tumor cells, detected by CellSearch, are predictive of short survival in several cancers and may serve as a liquid biopsy to guide therapy. Here we investigate the presence of EpCAM+ CTC detected by CellSearch and EpCAM- CTC discarded by CellSearch, after EpCAM based enrichment. EpCAM- CTC were identified by filtration and fluorescent labelling. This approach was validated using different cell lines spiked into blood and evaluated on blood samples of 27 metastatic lung cancer patients. The majority of spiked EpCAM+ cells could be detected with CellSearch, whereas most spiked cells with EpCAMlow or EpCAM- expression were detected using filtration. Five or more CTC were detected in 15% of the patient samples, this increased to 41% when adding the CTC detected in the discarded blood. The number of patients with CTC and the number of CTC detected were doubled by the presence of EpCAM- CTC. In this pilot study, the presence of EpCAM+ CTC was associated with poor outcome, whereas the EpCAM- CTC were not. This observation will need to be confirmed in larger studies and molecular characterization needs to be conducted to elucidate differences between EpCAM- and EpCAM+ CTC. [ABSTRACT FROM AUTHOR]